Mixed lineage leukemia (MLL)-fusion proteins can induce acute myeloid leukemias (AMLs) from either hematopoietic stem cells (HSCs) or granulocyte-macrophage progenitors (GMPs), but it remains unclear whether the cell of origin influences the biology of the resultant leukemia. MLL-AF9-transduced single HSCs or GMPs could be continuously replated, but HSC-derived clones were more likely than GMP-derived clones to initiate AML in mice. Leukemia stem cells derived from either HSCs or GMPs had a similar immunophenotype consistent with a maturing myeloid cell (LGMP). Gene expression analyses demonstrated that LGMP inherited gene expression programs from the cell of origin including high-level Evi-1 expression in HSC-derived LGMP. The gene expression signature of LGMP derived from HSCs was enriched in poor prognosis human MLL-rearranged AML in three independent data sets. Moreover, global 5 0 -mC levels were elevated in HSC-derived leukemias as compared with GMP-derived leukemias. This mirrored a difference seen in 5 0 -mC between MLL-rearranged human leukemias that are either EVI1 positive or EVI1 negative. Finally, HSCderived leukemias were more resistant to chemotherapy than GMP-derived leukemias. These data demonstrate that the cell of origin influences the gene expression profile, the epigenetic state and the drug response in AML, and that these differences can account for clinical heterogeneity within a molecularly defined group of leukemias.
INTRODUCTION
Acute myeloid leukemia (AML) is a hematopoietic disorder that results in accumulation of abnormal immature myeloid cells in the bone marrow (BM), spleen (SP) and peripheral blood (PB). Over 100 genetic alterations found in AML manifest in a wide range of clinical outcomes. 1 Some of the genetic alterations can be used as prognostic factors. However, cytogenetic markers indicate a trend rather than providing an absolute prediction of clinical outcome. 2, 3 Recently, multiple groups independently identified gene expression signatures associated with poor prognosis that are reminiscent of programs found in hematopoietic stem cells (HSCs), [4] [5] [6] which suggests that gene expression programs associated with normal hematopoietic development can influence patient outcome. However, the mechanisms that influence the expression of these programs are poorly defined.
Leukemias bearing translocations involving the mixed lineage leukemia (MLL) gene are found in 5-10% of AML. Over 50 different MLL fusion partners have been identified, but particular translocations show lineage specificity with the t(9;11) most common in AML. 7 MLL-rearranged leukemias are most often associated with clinically intermediate to unfavorable prognosis in clinical trials with 5-year disease-free survival rates of 30-60%. 8, 9 Studies nevertheless demonstrate heterogeneity of clinical outcomes within groups of patients with MLL rearrangements, which might be due to underlying biology of the disease. Such underlying biological differences in a cytogenetically homogenous group of AML may merit readjustment of therapeutics or treatment for individual patients based on additional risk assignment using biomarkers. Experiments with mouse models demonstrated MLL-rearranged AML (MLL-AML) may arise from hematopoietic stem and myeloid progenitor cells, 10, 11 making the leukemia cell of origin a possible source for some of the heterogeneity of clinical outcome.
We therefore hypothesized that biomarker and prognostic heterogeneity between MLL-AML patients might be a consequence of leukemogenic transformation occurring in a number of cell types in the hematopoietic hierarchy, including stem or committed progenitors, and that the cell of origin might influence the gene expression and epigenetic programs in the fully developed leukemias. To test this hypothesis we used mouse models of MLL-AF9 AML where leukemias arise from a defined cell type. Our findings show that MLL-AF9-mediated leukemogenic transformation differs when HSCs are the cells of origin as compared with granulocyte-macrophage progenitor (GMP). MLL-AF9-transformed HSCs are more likely to induce leukemia than are MLL-AF9-transformed GMPs. Functionally defined leukemia stem cells (LSCs) are immunophenotypically similar when initiated from HSCs or GMPs, but have differences in gene expression and DNA methylation that are determined by the cell of origin. These differences in gene expression and DNA methylation profiles 1 separate human MLL-rearranged AML cases into two groups with prognostic relevance. Finally, murine AML that originated from HSCs were less responsive to chemotherapy treatment in vivo than were leukemias derived from GMPs. These data show that the cell of origin can influence gene expression, epigenetic and drug response profiles in ways that are clinically relevant.
MATERIALS AND METHODS Patients
Thirty-five adult AML patient samples harboring a t(11q23) including 25 t(9;11) treated on AML HD93, HD98A, HD98B or AMLSG 07-04 were provided by the German-Austrian AML Study Group (AMLSG), with patient informed consent and institutional review board approval from all participating centers. 12 Twelve patients received an allogeneic BMT in first remission. Conventional chromosome banding and fluorescence-insitu-hybridization were performed at the central reference laboratory of the German-Austrian AMLSG. All samples included into the study contained at least 80% of leukemic cells following Ficoll-density-gradient centrifugation-based enrichment of samples.
Mice
Eight-to 12-week-old C57BL/6 mice (Charles River Laboratories, Wilmington, MA, USA) were used as BM donors and recipients. All mouse procedures were approved by the Institutional Animal Care and Use Committee. For detailed methods please refer to Supplementary data.
RESULTS

MLL-AF9-transduced HSCs induce leukemia more rapidly than MLL-AF9-transduced GMPs
We assessed the in vivo kinetics of AML development originating from MLL-AF9-transduced KLS (Lin
þ ) isolated from transgenic mice expressing luciferase under control of the ubiquitin promoter. 13 The expansion of leukemias was monitored using in vivo bioluminescent imaging of recipient mice at multiple time points after transplantation. Transplantation of 5-15 Â 10 3 MLL-AF9 expressing KLS (KLS:MA9) led to rapid accumulation of leukemic cells, whereas there was a 4-to 5-week delay in AML development when the same number of GMPs expressing MLL-AF9 (GMP:MA9) were transplanted. The median latency for the AML initiated from 5 Â 10 3 KLS:MA9 was 42 days vs 76 days for GMP:MA9 (data not shown). When 1.5 Â 10 4 KLS:MA9 or GMP:MA9 were transplanted the latencies were 37 and 58 days, respectively (Supplementary Figure 1a) . Next, we transplanted into secondary recipients 5 Â 10 3 total BM cells from mice that had succumbed to primary AML which originated from either KLS:MA9 or GMP:MA9. This led to the development of histopathologically similar diseases while maintaining a difference in the kinetics of disease development (Supplementary Figure 1b) . Leukemias derived from KLS possessed more clones than did leukemias initiated from GMPs as assessed by Southern blotting (Supplementary Figure 1c) Figure 1d) . Thus, we could not find evidence that differential homing of pre-leukemic cells has a role in leukemogenesis in this model. However, these data suggest that the cell of origin does influence development of the AML prompting further assessment.
HSC-derived clones initiate leukemia more rapidly and more efficiently than GMP-derived clones The leukemogenic process starts from a single cell. We transduced KLS, HSCs (CD34 À KLS) 16 or GMPs with the MIG control or MLL-AF9 retroviruses, and after 40 h resorted GFP þ cells at 1 cell/ well into 96-well plates containing semisolid media. Similar numbers of single-cell-sorted KLS:MA9 and GMP:MA9 colonies arose 17.1±8.4% and 21.5±6.7%, respectively. At the end of the 1st week, the clones were solubilized, and 500 cells were replated every 5-7 days for up to 9 weeks (Supplementary Figure 2a) . MIGcontrol-transduced GMPs and KLS exhausted after 1 to 3 replatings (data not shown), while replating efficiency between colonies initiated from HSCs:MA9, KLS:MA9 and GMP-MA9 was 50 ± 28.6%; 45.5 ± 35% and 78.6 ± 11.1%, respectively, averaged over five independent experiments (Figure 1a) . These experiments show that at a single-cell level MLL-AF9 equally immortalizes HSCs, KLS and GMPs in culture. Immunophenotypically KLS:MA9 and GMP:MA9 single-cell-derived clones (SCC) were indistinguishable by the presence of six surface markers including CD11b, Gr1, CD117, Sca1, CD34 and CD16/32 (Supplementary Figure 2b) . The single-cell clones that arose from KLS:MA9 and GMP:MA9 have similar numbers of retroviral integration sites assessed by Southern hybridization (Supplementary Figure 2c) . Expression levels of MLL-AF9 were slightly but not statistically significantly higher in HSC:MA9 as compared with GMP:MA9 (n ¼ 8, each). Also, expression levels of selected MLL-AF9 targets Hoxa9 (n ¼ 8, each), Meis1 (n ¼ 3, each) and Mef2c 20, 21 Furthermore, MLL-AF9 leukemias can be clearly separated into good and poor prognosis groups based on the presence or absence of EVI-1 expression. 22 These previous data point to biological differences between EVI1-positive and EVI1-negative MLL-fusion-mediated AML. We therefore assessed expression of Evi1 in LGMP from fully developed AML HSC and AML GMP . qPCR analyses (with three independent primer pairs) demonstrated that Evi1 expression levels were on average 200-fold higher in LGMP HSC than in LGMP GMP ( Figure 3a) . To further understand complexity of the two AML types, we then assessed gene expression differences between LGMP HSC (LH) and LGMP GMP (LG). RNA from LG, LH, KLS, common myeloid progenitors, GMPs and megakaryocyte-erythroid progenitors was extracted, amplified, labeled and hybridized to Affymetrix (Santa Clara, CA, USA) microarrays. Hierarchical clustering analysis of the expression profiles demonstrated that LG and LH are more similar to GMPs and to each other than to any other cell type assessed (Figure 3b ). Principal component (PC) analysis of the same data set demonstrated that the LGMPs were most similar to GMPs or perhaps a myeloid cell further downstream in myeloid development, but do have distinct gene expression programs dependent on the cell of origin (Figure 3c) . Of particular interest, we found that separation of samples along PC2 and PC3, which best separated KLS from more differentiated hematopoietic cells, revealed that LGMP HSC had a gene expression profile that appeared less differentiated than LGMP GMP (Figure 3d ). These data demonstrate that although globally most similar to a differentiating myeloid cell, LSCs derived from different cells of origin possess reproducible differences in gene expression.
LH signature is enriched in normal HSCs and is correlated with poor clinical outcome While expression of direct MLL-AF9 target genes was similar between LH and LG ( Supplementary Figure 4a) , comparative marker selection analysis demonstrated that 173 probesets (134 genes) have higher expression in LH (LH signature) while 1217 probesets showed higher expression in LG, the top 200 LG 594
LG 645
LG 688 LH 460 HMA LH 461 (Supplementary Figure 4b) . Gene set enrichment analysis demonstrated that the LH signature is expressed at higher levels in murine KLS when compared with GMPs (Po0.001) (Figure 3e ). The LH signature was then converted to human (HG_U133A) probesets or gene IDs and was also found to be enriched in human HSCs when compared with GMPs 23 (Po0.001) (Supplementary Figure 4c) . The LG signature showed a trend toward higher expression levels in mouse GMPs as compared with KLS (Po0.103) (Figure 3f ), but did not show any enrichment in human GMPs vs HSCs (Supplementary Figure 4d) . These data demonstrate that the reason HSC-derived LSCs are different from GMP-derived LSCs is that they express a more extensive HSC signature.
To assess the potential clinical relevance of the cell of origin associated gene expression programs on the resulting leukemia, we tested the correlation of expression of LG and LH signatures with clinical outcome in a group of 35 adult patients diagnosed with MLL-rearranged AML (MLL-AML) for which two sets of microarray data were available. 24, 25 Seventy two out of 121 LH signature and 113 out of 162 LG signature genes were present in the combined human data set, which were then used to cluster samples. Hierarchical clustering was used to separate gene expression profiles from 35 patients into those with high-and low-level expression of the LH or LG signatures ( Supplementary  Figure 5a and b) . Kaplan-Meier survival analysis demonstrated that patients with low-level expression of LH signature have longer relapse-free survival than those expressing high levels (Figure 4a ). The expression of the LG signature was less associated with the relapse-free survival in the same patients, even though there was a trend toward better survival for patients with leukemias that expressed higher levels of the LG signature (Figure 4b ). We further assessed the correlation of LH and LG signatures with clinical outcome in two previously published MLL-AML data sets. 2, 6 Similarly, hierarchical clustering was used to separate gene expression profiles from St Jude Children's Research Hospital (SJCRH) and Erasmus University Medical Center (EUMC) patients into those with high-and low-level expression of the LH signature. Kaplan-Meier survival demonstrated a trend toward longer relapse-free survival for patients whose leukemias had low LH gene expression than those expressing higher levels. But due to small numbers in both sets the correlation was not significant (Supplementary Figure 6a and  b) . Next, we used gene set enrichment analysis to assess whether expression levels of LH or LG signatures would demonstrate correlation with clinical outcome. For patients (n ¼ 21) treated at SJCRH poor outcome was considered relapse of the disease and good outcome-no relapse. For patients (n ¼ 15) treated at EUMC, good outcome group contains patients who were in remission after the first cycle of treatment and poor outcome contains patients who were not. Expression of the LG signature again did not correlate with clinical outcome in either data set. However, expression of the LH signature correlated with poor clinical outcome in both SJCRH (Supplementary Figure 6c) and EUMC MLL-AML (Supplementary Figure 6d) data sets. Of interest, the LH signature only correlated with poor clinical outcome in MLL-AMLs, and not in other select groups of AML samples ( Table 1) .
Composition of the LH signature was further analyzed using leading edge overlap in gene set enrichment analysis. 26 Out of 121 genes in the LH signature (converted to human HG-U133A_2), the leading edge in EUMC data set consisted of 52 genes, whereas in the SJCRH data set leading edge was 37 genes. Twenty genes (Po0.002) were in common between SJCRH and EUMC leading edge data sets (Supplementary Table 1 , Supplementary Figure 5c ). This procedure shows that the LH signature contains a subsignature that is particularly strongly associated with poor clinical outcome in MLL-AML. To test the significance of the 20 genes (LE20), we assessed for enrichment of LE20 signature in the poor prognosis group from our data set (n ¼ 35) and again found significant enrichment in poor clinical outcome group (Supplementary Figure 6e) . qPCR analysis demonstrated higher expression of 15 out of LE20 genes in LGMP HSC over LGMP GMP (n ¼ 3 for each) (Supplementary Figure 6f) . These data demonstrate that in a mouse model of MLL-AF9 AML an HSC cell-oforigin-associated signature correlates with poor clinical outcome in human AML.
LGMP GMP Relapse free survival, days Figure 4 . Correlation of LH and LG signatures expression with clinical outcome. Kaplan-Meier analysis for relapse-free survival comparing the cluster-defined subset of samples with high and low levels of LH signature gene expression (a) and high and low LG signature expression (b). P-value was calculated using log-rank test. 
Cell of origin in MLL-rearranged AML AV Krivtsov et al and correlate with leukemia patients' clinical outcomes irrespective of gene expression patterns. 27 Recently we demonstrated that EVI1-positive and EVI1-negative MLL-AML differ morphologically and phenotypically. 19 Moreover expression of EVI1 in human AML correlated with poor outcome. 20 Furthermore, loss of one allele of DNMT1 leads to a reduction of 5 0 -mC levels and subsequently a less aggressive MLL-AF9-mediated AML. [28] [29] [30] We therefore wanted to assess DNA methylation to see whether differences might be associated with good vs poor outcome in human leukemias and with murine leukemias derived from different cells of origin.
Direct comparison of 5 0 -mC profiles in EVI1 þ and EVI1 À MLL-AML samples (from GSE18700) analyzed using the HELP assay 31 revealed 260 differentially methylated regions annotated to 296 genes. Globally, EVI1
þ MLL-AMLs demonstrated higher 5 0 -mC levels as compared with EVI1
À MLL-AMLs (Figure 5a ). This shows within the molecularly defined MLL-AML group of leukemias there is a poor prognosis group (EVI1 þ ) that have relatively high levels of 5 0 -mC and there is a better prognosis group (EVI1 À ) that have relative low levels of 5 0 -mC. Next we assessed 5 0 -mC levels in LGMP HSC and LGMP GMP using the enhanced reduced representation bisulfite sequencing assay 29 and we identified 4088 differentially methylated sites (GSE43333). Similar to the human EVI1 þ MLL-AMLs, LGMP GMP were hypomethylated as compared with LGMP HSC (Figure 5b ), thus demonstrating that relative high levels of 5 0 -mC are found in poor prognosis human MLL-AML and murine MLL-AF9 AML derived from HSCs. These data show that using AML samples originated from HSCs and committed progenitors we were able to reproduce the diversity of global 5 0 -mC levels observed in primary human MLL-AMLs.
HSC-derived AML are less responsive to cytarabine and doxorubicin than GMP-derived AML We have established that AMLs derived from different cells of origin possess differences in the kinetics of disease development, inherit gene expression differences that define the cell of origin and differences in 5 0 -mC levels. Taken together with several previous reports that found a correlation between poor clinical outcome of AML patients and elevated expression of HSC-specific genes, 5, 6, 32 we hypothesized that AML originated from HSCs and GMPs may respond differently to therapeutics. To test this hypothesis we assessed the sensitivity of AML HSC and AML GMP in vitro to a commonly used chemotherapeutic drug doxorubicin. Total BM cells (490% GFP þ cells) from primary recipient mice that had succumbed to AML were exposed to serial dilutions of doxorubicin for 2 days followed by assessment of live cells using an MTT assay. The cell survival assay established IC50 concentrations for AML HSC and AML GMP B80 and 20 ng/ml, respectively (Figure 6a) . We further assessed response of AML HSC and AML GMP to one cycle of conventional chemotherapy, similarly to a previously reported protocol. 33 Secondary recipient mice were transplanted with 2 Â 10 3 total BM cells from primary mice that had succumbed to either AML HSC (n ¼ 8) or AML GMP (n ¼ 11). Starting on day 10 the mice were bled from the tail vein twice weekly followed by FACS for GFP þ leukemia cells. When the percentage of GFP þ cells in PB reached 20-40% levels, the mice were split into two groups; one group was treated for 5 days with Ara-C (100 mg/kg) and 3 days with doxorubicin (3 mg/kg) according to Zuber et al., 33 and the other group was not treated. The AML burden was assessed 12 days after the initial treatment in BM, PB and SP (Figure 6b ). One cycle of chemotherapy significantly reduced the percentage of AML GMP cells in PB from 81.9 ± 1.5 to 53.1 ± 17.3% (Po0.01), while there was an insignificant trend to reduction of AML HSC cells from 77.1±9.9 to 53.3±9.2% P ¼ 0.07). The treatment did not significantly affect AML HSC cells in BM or SP, while it clearly reduced the percentage of AML GMP from 93.5 ± 2 to 70.2 ± 9.7% (Po0.02) in BM and from 71.4 ± 3.3 to 38.3 ± 6.2% in SP (Po0.02) (Figure 6c ). Similarly the treatment did not significantly reduce splenomegaly in mice developing AML HSC while SP weights in mice with AML GMP cells were reduced from 510 ± 29 to 375 ± 60 mg (Po0.01) (Figure 6d ). These data suggest that 2207  2288  6238  5351  7072  2285  3316  5358  6364  7166  7306   EVI1+  EVI1-949  950  499  956  459 460 955
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LG / Evi1- resistance to chemotherapy may be in part governed by cellular machinery active in HSCs that is maintained in LSCs derived from HSCs, and help explain why patients that have leukemias with high-level expression of HSC gene expression programs do poorly.
DISCUSSION
In this study we have experimentally addressed the question as to whether the cell of origin can influence the phenotype of the resulting leukemia and LSCs. We demonstrate that MLL-AF9 transforms HSCs and GMPs at a single-cell level. In vitro experiments demonstrated similar efficiency of immortalization, while in vivo, the kinetics and frequency of leukemia development is greater for clones initiated from HSCs. We also show that the immunophenotype of the cellular population enriched for LSC activity in both HSC-and GMP-derived leukemias is most consistent with a mid-myeloid cell (LGMP). However, leukemias that originate from HSCs retain enhanced expression of a set of 'stem cell-associated' genes (LH signature). Patients whose leukemia samples express higher levels of the LH signature have a shorter relapse-free survival as compared with patients whose samples express less of the LH signature. Moreover, leukemias derived from HSCs demonstrate less of a response to doxorubicin and cytarabine than do leukemias that arise from GMPs. These data show that the cell origin influences the ultimate biology of the leukemia that arises, and establishes clinically relevant gene expression differences that are determined by the cell of origin.
Longstanding questions in cancer biology include the cell of origin of specific cancers and whether differences in the cells of origin from one cancer to the next might influence the clinical behavior of the resultant cancer. 34 Recent studies have utilized mouse models of leukemia and other cancers to demonstrate that cancer can arise from multiple cell types within a tissue [35] [36] [37] reviewed in Krivtsov and Armstrong. 7 In AML it is clear that certain fusion oncoproteins such as BCR-ABL are only capable of initiating disease when expressed in HSCs, whereas other oncogenes such as MLL-AF9 and MOZ-TIF2 can transform both HSCs and more committed progenitor cells. 10, 11, 38 However, it has been unclear whether expression of an oncogene in different developmental cell types within a tissue can influence the phenotype of the resulting leukemia and LSCs. Our data directly addresses this question and demonstrate that the cell in which MLL-AF9 is expressed influences the resultant behavior, gene expression and epigenetic programs of the LSCs even if the immunophenotype of the leukemia and LSCs is similar.
Globally the LSCs derived from either HSCs or GMPs are most like a mid-myeloid progenitor cell, likely representing a cell just downstream of the normal GMPs. Even though the immunophenotype is similar for LSCs derived from different cells of origin, there are reproducible differences in gene expression. For example, Evi1, c-jun, Fos1, Bcl6, 39 Gsr1, Nedd9 and Zfp36 40 are highly expressed in HSC-derived LSCs but not GMP-derived LSCs (Supplementary Figure 6f) . Therefore, we demonstrate that the cell in which the oncogene is initially expressed can influence the final gene expression program of the LSCs even if the LSC represents a stage of hematopoietic development further downstream of the HSCs. Thus, it appears that expression of MLL-AF9 in GMPs activates a stem cell-associated program that is sufficient to induce leukemia, but that expression of MLL-AF9 in HSCs allows maintenance of a more extensive stem cell-derived program that influences the LSC behavior.
The findings presented here provide insight into the diversity of gene expression in AML. It appears that we have modeled high-risk MLL-AML arising from chromosomal translocation Cell of origin in MLL-rearranged AML AV Krivtsov et al arising in HSCs. Our data suggest that it is likely that other goodrisk MLL-AML arise from more differentiated myeloid progenitors that likely include but may not be limited to GMPs. Gene expression analyses performed on human leukemias have demonstrated that differences in gene expression between various leukemias can in part be described by the presence of recurrent mutations including chromosomal translocations. 2, 6 Emerging genomic-scale assessment of DNA methylation profiles suggests a second level of heterogeneity. 41, 42 However, the biological mechanisms that influence gene expression and epigenetic programs beyond recurrent mutations are largely unknown. Our data suggest that the epigenetic state of the cell in which the oncogene is initially expressed (in this case HSCs vs GMPs) contributes to the final gene expression and epigenetic program of the leukemia in a manner that impacts the overall behavior and drug response. If, at the time of acquisition of an oncogenic event, the epigenetic state of a cell determines what genes/programs can be activated, then one can predict that the combination of the cell of origin or overall epigenetic state combined with genetic changes will determine the final gene expression profile.
Recent studies in breast cancer cell lines and mouse models of pancreatic cancer have demonstrated that the epigenetic state of cells before full transformation can influence which cells give rise to cancer. 43, 44 These reports suggest that an aberrant signal or injury can induce epigenetic changes that enhance transformation potential. Studies of mouse models of brain tumors established that glioblastoma might arise from genetic lesions in neural stem cells, as well as in glial progenitors reviewed in Chen et al., 45 and the cell of glioma origin influenced developmental characteristics of the tumors. 46 Genomic correlation studies of human glioblastoma samples established that subtypes of gliomas often share molecular signatures with normal neural cell types. 47 However, due to the lack of a detailed understanding of neural development as compared with hematopoietic development, the direct relationship between cell of origin and subtypes of Gliomas has remained unclear. Recently it has been documented in detail how the cell of origin influences the phenotype of iPSC. 48, 49 Our data are in line with these concepts in that cells at different stages of development can be transformed with the same oncogene and produce LSCs that, although similar, have reproducible differences in gene expression that are clinically relevant and show that these cell of origin-based differences recapitulate what is seen in clinical samples. Indeed it appears that LSC express specific genes and carry levels of DNA methylation that are determined by the cell of origin and that the unique gene expression profiles might serve as a cellular 'memory' of the cell in which the oncogene was first expressed. Together, these data contribute to growing evidence that the process of cancer development is driven by genetic mutations in oncogenes and tumor suppressors, which interact with the epigenetic landscape to give rise to a tumor with unique biological and clinical behavior. 50, 51 These data predict that a combination of therapies that target genetic changes and epigenetic programs will be synergistic in their ability to eradicate tumors. A major focus is to determine how to appropriately combine modulators of epigenetic programs and genetically targeted therapies for clinical benefit.
